Increased gut permeability and bacterial translocation are associated with fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome: implications for disease-related biomarker discovery. — CFSMEATLAS
Increased gut permeability and bacterial translocation are associated with fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome: implications for disease-related biomarker discovery.
Martín, Franz, Blanco-Suárez, Manuel, Zambrano, Paola et al. · Frontiers in immunology · 2023 · DOI
Quick Summary
This study found that people with ME/CFS and fibromyalgia may have a 'leaky gut'—where the intestinal barrier doesn't work as well as it should. Researchers measured several substances in the blood that indicate gut barrier problems and inflammation, and found higher levels in both patient groups compared to healthy people. These findings suggest that gut dysfunction might play a role in these conditions and could eventually help doctors identify and understand these diseases better.
Why It Matters
This study provides objective, measurable biomarkers that may help validate gut barrier dysfunction in ME/CFS—a finding that could explain some GI symptoms and guide future treatment strategies. Identifying specific biomarkers could accelerate diagnostic development and reveal pathophysiological mechanisms underlying both conditions. The correlation between biomarkers and autonomic symptoms (COMPASS-31) offers new insight into potential mechanisms linking gut dysfunction to systemic ME/CFS features.
Observed Findings
FM patients had significantly higher anti-β-LGB, zonulin-1, LPS, and sCD14 levels than healthy controls (all P<0.0001).
ME/CFS patients showed elevated levels of these same four biomarkers compared to controls, but lower than FM patients (all P<0.01).
Anti-β-LGB and zonulin-1 correlated significantly with LPS and sCD14 in both patient cohorts (P<0.001).
In FM, anti-β-LGB and zonulin-1 correlated with SF-36 health scores; in ME/CFS, zonulin-1 correlated with autonomic dysfunction severity (COMPASS-31).
ROC curve analysis showed strong discriminatory ability of these four biomarkers to distinguish both conditions from healthy controls (P<0.0001).
Inferred Conclusions
Intestinal barrier dysfunction and bacterial translocation biomarkers are elevated in both FM and ME/CFS, with FM showing more severe impairment than ME/CFS.
These biomarkers correlate with disease-specific symptoms, particularly autonomic dysfunction, suggesting a potential mechanistic link between gut barrier integrity and systemic manifestations.
Anti-β-LGB, zonulin-1, LPS, and sCD14 may serve as putative diagnostic or stratification biomarkers for these conditions, though further validation is required.
Remaining Questions
Do these biomarker abnormalities precede symptom onset, or do they develop secondarily to disease processes?
What This Study Does Not Prove
This study does not prove that gut barrier dysfunction causes ME/CFS or fibromyalgia—it only shows they occur together (correlation, not causation). The cross-sectional design means we cannot determine whether barrier dysfunction precedes symptom onset or develops as a consequence. Results are preliminary and require validation in larger, longitudinal studies before these biomarkers can be used clinically.
What is the biological mechanism linking intestinal barrier dysfunction to the systemic and neurological symptoms of ME/CFS?
Can therapeutic interventions targeting gut barrier function (e.g., dietary modifications, probiotics, zonulin inhibitors) improve ME/CFS and FM symptoms, and would biomarker improvement predict clinical response?
Are these biomarkers specific to FM and ME/CFS, or are they elevated in other chronic inflammatory or fatigue conditions?